BioCentury
ARTICLE | Financial News

SciClone discontinues pancreatic cancer trial

October 6, 2009 1:32 AM UTC

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) fell $0.42 (10%) to $3.73 on Monday after discontinuing a Phase II trial of RP101 (BvdU) to treat advanced pancreatic cancer based on the recommendation of ...